Introduction {#s1}
============

Chronic cholecystitis is one of the most prevalent diseases requiring surgical intervention. In China, more than 90% of the cholecystitis cases are claimed to be caused by symptomatic cholelithiasis, the incidence of which is approximately 10% of the adult population. [@pone.0070265-Hsing1], [@pone.0070265-Andreotti1] Histologically, chronic cholecystitis presents a large range of related inflammatory epithelial changes including mononuclear infiltrate, fibrosis, thickness of muscular layer, dysplasia, hyperplasia and metaplasia-the last three have been considered as premalignant lesions. [@pone.0070265-Roa1]--[@pone.0070265-Duarte1].

The causes of chronic cholecystitis still remain unclear. Recently, many findings obtained from microbiological studies suggest that bacterial infection in biliary system might play a role. Our previous meta-analysis demonstrated that *Helicobacter pylori* (*H.pylori*) in human biliary system was correlated with chronic cholecystitis, especially in the regions with higher prevalence of this infectious agent such as South Asia, East Asia and Latin America. [@pone.0070265-Zhou1] Evidences supporting the association between *H.pylori* infection and chronic cholecystitis could be found by using direct culture or staining of *H.pylori* in gallbladder tissues as well as indirect techniques such as PCR, ELISA and serology for detecting *H.pylori*-specific genes or antibodies.[@pone.0070265-Lee1]--[@pone.0070265-Pandey1] The positive rate of *H.pylori* in gallbladder is reported to be 10%--20% by culture. [@pone.0070265-Chen1].

*H.pylori* can induce oxidative stress through producing reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are considered to be the important causes of chronic inflammation, ulcer and canceration of the stomach. [@pone.0070265-Handa1] In *H. pylori*-infected stomach, possible sources of ROS/RNS include neutrophils, vascular endothelial cells, gastric mucosal cells, and *H. pylori* itself. One of the most important pathways of *H.pylori*-induced RNS is mediated by overproduction of endogenous synthesis nitric oxide (NO) through inducible NO synthase (iNOS) expression. [@pone.0070265-Tonkic1] In benign inflammatory and malignant gallbladder diseases, ROS and iNOS also play an important role. [@pone.0070265-Zhang1] However, in biliary system, the correlation between *H.pylori* and ROS/RNS production still needs further investigation.

Two-thirds of the world population is infected with *H.pylori*. [@pone.0070265-Correa1] The findings of *H.pylori* in biliary tract implicated that the stomach might not be the only arena of activity of this agent. However, few studies by far have specifically assessed the characteristics of "*Helicobacter pylori* positive cholecystitis". Therefore, this study aims to compare the clinicopathological features between chronic cholecystitis patients with and without *Helicobacter pylori* infection in gallbladder mucosa.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

Of 378 patients who underwent cholecystectomy in Department of General Surgery, Xinhua Hospital from December 2011 to July 2012, three hundred and twenty-six patients (97 males and 229 females, aged 21--87 years) who fulfilled the pathological criteria of chronic cholecystitis were enrolled in this study. The exclusion criteria were: (1) patients with history of hepato-biliary or pancreatic surgery which changed the normal structure and function of the biliary system, (2) patients who had previously received standard triple therapy for *H. pylori* eradication, (3) patients who had taken antibiotics or proton pump inhibitors 4--6 weeks prior to cholecystectomy. According to whether *H. pylori* was detected positive in gallbladder mucosa, patients were divided into two groups. The study protocol was approved by the Ethics Committee of Shanghai JiaoTong University, School of Medicine and signed informed consent was obtained from all the patients.

Gastroscopy {#s2b}
-----------

Before or after cholecystectomy, all patients enrolled in this study received gastroscopy with biopsy in order to clarify the infection status of *H. pylori* in their stomach. Gastroscopy was performed with video endoscopes that worked in high-resolution, white light mode and AFI mode (EVIS-FQ260Z; Olympus Medical Systems Co. Ltd, Tokyo, Japan). Two biopsy specimens were taken at each site from the greater curvature of the antrum, and the greater and lesser curvature of the corpus. Each of the two specimens from the above parts of the stomach were used respectively for culture and Warthin-Starry Staining of *H. pylori*.

Cholecystectomy and Gallbladder Biopsy {#s2c}
--------------------------------------

Laparoscopic cholecystectomy was performed by a single surgeon using a standardized 4-port technique (Laparoscopic Device, KARL STORZ GmbH, Tuttlingen, Germany). Two biopsy specimens were taken aseptically at each site from the fundus, body and neck of the gallbladder. Each of the two specimens from the above parts of the gallbladder were used respectively for culture and Warthin-Starry Staining of *H. pylori*.

The stomach and gallbladder specimens were aseptically transferred to the microbiology laboratory immediately after gastroscopy or cholecystectomy.

Verification of *H. pylori* Infection in Gallbladder and Stomach {#s2d}
----------------------------------------------------------------

The presence of *H. pylori* in gastric or gallbladder mucosa was determined by either positive culture, Warthin-Starry Staining or positive nest PCR for specific 16s rRNA of this bacterium. At least one positive test was regarded as confirmation of infection of this agent in gallbladder or gastric mucosa.

Culture of *H. pylori* {#s2e}
----------------------

The gallbladder and gastric mucosa specimens were inoculated onto sterile plates containing endo agar and Brucella agar supplemented with 5% horse blood (Becton, Dickinson and Company, Sparks, Maryland, USA) for nonspecific bacterial and *Campylobacter* cultures, respectively. For isolation of *H.pylori*, we prepared specific media containing BHI agar supplemented with 7% sheep blood, 0.4% IsoVitaleX (Becton, Dickinson and Company, Sparks, Maryland, USA) and Skirrow-selective supplements (Oxoid Limited, Thermo Fisher Scientific, Hampshire, UK). *H.pylori* was incubated at a microaerophilic condition (5% O~2~, 10% CO~2~, 85% N~2~) for 3--7 days at 37°C. Bacteria colonies were examined with biochemical tests as well as microscopy for conformation. *H. pylori* colony was identified as showing the typical white, pin-point and transparent morphology. Oxidase and fast urease activity were also performed at colonies grown on *H. pylori* specific media. Bacterium with typical morphology, positive oxidase and urease activity were verified as *H. pylori*.

Warthin-Starry Staining of *H. pylori* {#s2f}
--------------------------------------

Warthin-Starry Staining was performed using the specific kit (Diagnostic BioSystems, Pleasanton, California, USA). Four-micrometer thick paraffin sections of gallbladder and gastric mucosa tissues from each patient were backed for 1 h at 60°C. After dewaxing and re-hydration, sections were incubated at 56°C for 1 h in 1% silver nitrate buffer in the dark box and then dipped in developer solution and stained for 5--8 min. Finally, sections were dehydrated with 100% alcohol, cleared with xylene. *H. pylori* was identified as stained into buffy or black color in a light yellow background under microscope with oil immersion lens (×1000). The results were also determined independently by the above two pathologists. Warthin-Starry staining and *H. pylori* culture were blindly assayed for all the specimens from each patient.

PCR for *Helicobacter* 16s rRNA Gene {#s2g}
------------------------------------

The DNA extracts were prepared from the paraffin specimens as the kit (TIAN amp Micro DNA kit, TIANGEN Biotech, Beijing, China) instructed. A semi-nested PCR assay specific for *Helicobacter* 16s rRNA gene (16s rDNA) was amplified as previously described [@pone.0070265-Karagin1], using primers 1F (5′CTATGACGGGTATCCGGC3′), 1R (5′CTCACGACACGAGCTGAC3′) and 2R (5′TCGCCTTCGCAATGAGTATT3′). Primers 1F and 1R were used in the first step, whereas primers 1F and 2R were used in the second step. The PCR reaction mixture contained 1 µl of 10 µM each primer (1F and 1R), 2 µL of 10 mM dNTP, 1×PCR reaction buffer, 2.5 mM MgCl2, 0.05% casein, 0.05% formamid, 1.25 U rTaq DNA polymerase (Takara, Dalian, China), and 2 µL extracted DNA as templates. The amplification conditions for the first step were 94°C for 2 min; 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and finally 72°C for 10 min. The reaction mixture of the second step (25 µL) contained 0.5 µl of 10 µM each primer each primer (1F and 2R), 0.2 mmol/L each dNTP, 1×PCR reaction buffer, 2.5 mmol/L MgCl2, 1.0 U ExTaq DNA polymerase (Takara, Dalian, China), and 2 µL 10×diluted PCR product from the first step. The 416-bp PCR products were visualized by 1.2% agarose gel electrophoresis.

Sequence Analysis {#s2h}
-----------------

The PCR products were subsequently ligated into pMD-19T simple vector (Takara, Dalian, China) for sequencing. The product was sequenced after PCR amplification and double enzyme digestion. The sequences were compared with the 16S rRNA gene sequences of the strains that have been registered in the GenBank database. Products of the sequence reaction were aligned and the closest homologous sequence was identified by Standard Nucleotide BLAST analysis tool on the internet (BLASTn, <http://blast.ncbi.nlm>. nih.gov).

Histological Analysis of Chronic Cholecystitis {#s2i}
----------------------------------------------

Gallbladder specimens were fixed in 10% buffered formalin and embedded in paraffin. Four micrometer-thick sections were cut and stained with hematoxylin-eosin (HE). Sample slides were examined independently by two attending pathologists who specialized in biliary diseases and in the case of discrepancy, the decision was made by discussion or in consultation with a third experienced pathologist. Chronic inflammation was diagnosed in the presence of a predominantly mononuclear inflammatory infiltrate, fibrosis, or metaplastic changes. A scoring system proposed by Barcia JJ [@pone.0070265-Barcia1] was used to semi-quantitatively assess the histological changes of chronic cholecystitis ([Table 1](#pone-0070265-t001){ref-type="table"}).

10.1371/journal.pone.0070265.t001

###### Definitions of Pathological Changes of Chronic Cholecystitis.

![](pone.0070265.t001){#pone-0070265-t001-1}

  Pathological Changes of Chronic Cholecystitis                                                         Definition
  ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Inflammatory mononuclear infiltrate             
  Mild                                                                             Diffuse, ≤10 inflammatory cells per HPF in any layer
  Moderate                                                                               Diffuse, between 11 to 30 cells per HPF
  Severe                                                                            Diffuse, more than 31 cells per HPF or follicular
  Degree of fibrosis                              
  Mild                                                                                Uneven collagen deposition in ≤20% of material
  Moderate                                                                         Uneven collagen deposition in 21% to 70% of material
  Severe                                                                       Uneven collagen or lamellar fibroplasia in ≥71% of material
  Thickness of the muscular layer                 
  Mild                                                                                  Less than one third of the whole thickness
  Moderate                                                                                 One third to two thirds of the wall
  Severe                                                                                More than two thirds of the wall thickness
  Addipose tissue deposition                      
  Mild                                                                                          Up to 10% of the material
  Moderate                                                                                      11% to 60% of the material
  Severe                                                                                      More than 60% of the material
  Degree of hyperplasia                           
  Diffuse                                                                                       ≥70% of the whole sections
  Focal                                                                                        \<70% of the whole sections
  Degree of dysplasia                             
  Low-grade                                                                Resemble tubular adenomas of the colon without intestinal metaplasia
  High-grade                                                                      Markedly pleomorphic nuclei and/or prominent nucleoli
  Metaplasia                                      
  Pyloric type                                                                Structures similar to the pyloric glands in the lamina propria
  Intestinal type                                                                          Goblet cells and enterocitlike cells
  Gastric surface type                             Epithelial cells of gallbladder mucosa replaced by tall columnar cells with abundant mucin and basallylocated nuclei

HPF: high power field.

Immunohistochemical Staining of iNOS and ROS {#s2j}
--------------------------------------------

For iNOS and ROS detection, immunohistochemistry was performed on 4-µm thick, mounted on silane-coated slides of gallbladder mucosa tissue sections. Sections were deparaffinized and rehydrated, then washed in distilled water and 0.05 mol/L Tris buffer. After blocking the nonspecific binding sites by using Protein blocking agent (Coulter-Immunotech, Marseille, France), sections were incubated with the primary polyclonal rabbit anti-iNOS and ROS antibody (1∶200, Transduction Laboratories, kentucky, USA) at 4°C for 24 h. After sections were washed, a biotinylated immunoglobulin (anti-rabbit serum for iNOS and ROS) was applied for 30 min. Finally, all sections were incubated with the avidine-biotin-complex (ABC) with alkaline phosphatase (Vectastain, Vector Laboratories, Burlingame, California, USA). The staining was visualized with 3,3′-diaminobenzidine and hydrogen peroxide.

Semiquantitative analysis of the iNOS and ROS immunostaining was performed independently by the above two pathologists and in the case of discrepancy, the decision was made by discussion or in consultation with a third experienced pathologist. In ten randomly selected areas of the whole section, the number and percentage of positive cells were calculated for determining staining intensity and proportion of iNOS or ROS staining. A case without positive cells was considered negative. A case with less than 10% positive cells was scored 1, 10--50% was scored 2, 50--80% was scored 3 and more than 80% was scored 4. A staining intensity was classified as weak (I), moderate (II) and strong (III). A immunoreactive score was calculated as staining intensity×amount of positive cells (from lowest score 0 to highest 12) and specimen with a grade of more than 1 was defined as positive. [@pone.0070265-Kasper1].

Statistical Analysis {#s2k}
--------------------

The software SAS 9.13 (SAS Institute, Gary, North Carolina, USA) was used for conducting statistical analysis. Student's t-test was performed for comparing age and BMI. The immunoreactive score of iNOS and ROS were calculated and statistically compared between the two groups using Mann-Whitney *U*-test. Chi-square test or Fischer's exact test was used to examine the rest clinicopathological parameters. For all statistical analyses, significance levels were set at *p*\<0.05.

Results {#s3}
=======

Evidence of *H. pylori* in gallbadder mucosa was demonstrated by Warthin-Starry staining in 64 (19.63%) patients and *H. pylori* colonies were identified upon culture in 55 (16.87%) patients. Among them, 52 (77.61%) patients were both positive in staining and culture. In PCR test for *Helicobacter-*16s rRNA gene, 67 (20.55%) patients were positive. From all the gallbladder specimens, only the positive samples which detected by staining or culture were positive in nest PCR test. All samples positive for first-step amplicon were also positive for the nested PCR. Finally, *H. pylori* infection in gallbladder mucosa was detected in 20.55% (n = 67) of the cholecystitis patients ([Figure 1](#pone-0070265-g001){ref-type="fig"} and [2](#pone-0070265-g002){ref-type="fig"}). These patients had a higher prevalence of acid regurgitation symptoms (*p* = 0.001), more histories of chronic gastritis (*p* = 0.005), gastric ulcer (*p* = 0.042), duodenal ulcer (*p* = 0.026) and a higher positive rate of *Helicobacter pylori* (*p*\<0.05) in the stomach as compared to patients without *Helicobacter pylori* infection in the gallbladder ([Table 2](#pone-0070265-t002){ref-type="table"}). Of the 67 patients (20.55%) who were positive in *H. pylori* 16s rRNA detection in gallbladder mucosa, amplications of 16s rRNA in their gastric or duodenal specimens were also succeed in 42 patients (62.69%). These were 30 of 45 (66.67%) patients with chronic gastritis, 7 of 11 (63.64%) patients with gastric ulcer and 5 of 8 (62.50%) patients with duodenal ulcer ([Figure 2](#pone-0070265-g002){ref-type="fig"}). Consequently, we check the amplified PCR products by direct sequencing and BLAST search and confirmed that each sequence was 96--99% similar to a known *H. pylori* 16s rRNA gene registered in GenBank ([Figure 3](#pone-0070265-g003){ref-type="fig"}). No other kinds of *Helicobacter* species such as *Helicobacter bilis*, *Helicobacter hepaticus* or *Helicobacter pullorum* could be detected by PCR. Moreover, our data also revealed that *H. pylori*-16s rRNA in gallbladder and gastric (or duodenal) mucosa acquired from the same individual patient had identical sequences ([Figure 4](#pone-0070265-g004){ref-type="fig"}).

![*H.pylori* infection in metaplastic gallbladder mucosa (oil immersion lens,×1000, red arrow indicates *H.pylori*).](pone.0070265.g001){#pone-0070265-g001}

![PCR products of *Helicobacter* specific 16s rRNA gene from gallbladder and gastric mucosa samples.\
(lanes M: step-ladder marker; 1: positive control of gastric biopsy-derived *H. pylori* DNA; 2: negative control of gastric biopsy; 3: negative 16s rRNA gene in gallbladder; 4 and 5: negative 16s rRNA gene in gallbladder and gastric mucosa acquired from one individual patient; 6 and 7: positive 16s rRNA gene in gallbladder and gastric mucosa acquired from another individual patient).](pone.0070265.g002){#pone-0070265-g002}

![Comparison of complete sequence data of *H.* *pylori* 16s rRNA gene tested in gallbladder mucosa sample from published GenBank data: sequence ID ref\|NR_044761.1\|.\
(nucleotides 263--695 were listed).](pone.0070265.g003){#pone-0070265-g003}

![BLAST showed *H.* *pylori* 16s rRNA gene in gallbladder and gastric mucosa from the same individual patient had completely identical sequences.\
(sequence ID50661: H. *pylori* 16s rRNA tested in gallbladder mucosa; sequence ID50659: H. *pylori* 16s rRNA tested in gastric mucosa).](pone.0070265.g004){#pone-0070265-g004}

10.1371/journal.pone.0070265.t002

###### Clinical characteristics of *H.pylori*-positive and negative chronic cholecystitis.

![](pone.0070265.t002){#pone-0070265-t002-2}

  Characteristics                                 No. of Patients n (%)                        
  ---------------------------------------------- ----------------------- --------------------- -----------------------------------------------------------------------------
  Age (yr)                                             45.54±12.58            47.82±11.56                                           NS
  Gender                                                                                       
  Male: Female (% Male)                               19∶48(28.36)           78∶181(30.12)                                          NS
  BMI (kg/m^2^)                                        23.10±2.24             22.72±1.85                                            NS
  Symptom                                                                                      
  Mild Abdominal Pain                                   44(65.67)             149(57.53)                                            NS
  Biliary Colic                                         32(47.76)             102(39.38)                                            NS
  Loss of Appetite                                      12(17.91)              28(10.81)                                            NS
  Acid Regurgitation                                    22(32.84)              39(15.06)                          0.001[\*](#nt102){ref-type="table-fn"}
  Heartburn                                             20(29.85)              50(19.31)                                            NS
  Preoperative Ultrasound Diagnosis                                                            
  Gallstone Disease                                                                            
   No. of Gallstones                                                                           
   Single: Multiple (% Single)                        21∶34(38.18)          104∶108(49.06)                                          NS
  Polypoid Lesion                                                                              
   No. of Polypoid Lesions                                                                     
   Single: Multiple (% Single)                         8∶4(66.67)            18∶31(35.29)                                           NS
  Gallbladder Wall Thickening                           12(17.91)              39(15.06)                                            NS
  Atrophic Gallbladder                                  15(22.39)              35(13.51)                                            NS
  History of Other Gastrointestinal Diseases                                                   
  Chronic Gastritis                                     45(67.16)             124(47.88)                          0.005[\*](#nt102){ref-type="table-fn"}
  Gastric Ulcer                                         11(16.42)              21(8.11)                            0.042[▴](#nt103){ref-type="table-fn"}
  Duodenal Ulcer                                        8(11.94)               12(4.63)                            0.026[▴](#nt103){ref-type="table-fn"}
  Reflux Esophagitis                                    12(17.91)              25(9.65)                                             NS
  Chronic Enteritis                                      3(4.48)                8(3.09)                                             NS
  *H.pylori* (+) in Gastric or Duodenal Mucosa                                                 
  Warthin-Starry Stain                                  39(58.21)             106(40.93)                           0.011[▴](#nt103){ref-type="table-fn"}
  * H.pylori* Culture16s rRNA gene PCR             33(49.25)42(62.69)     90(34.75)115(44.40)   0.029[▴](#nt103){ref-type="table-fn"}0.008[\*](#nt102){ref-type="table-fn"}

*p*\<0.01.

*p*\<0.05.

NS: not significant.

N/A: not applicable.

The results of comparison of pathological features between the two groups in gallbladder mucosa were demonstrated in [Table 3](#pone-0070265-t003){ref-type="table"}. Higher incidences of adenomyomatosis (*p* = 0.012) and metaplasia (*p* = 0.022) were detected in *H. pylori* infected gallbladder mucosa ([Figure 5](#pone-0070265-g005){ref-type="fig"}). The metaplastic lesions were predominantly of pyloric type (21 cases, 84% from the total of metaplastic cases), characterized by structures similar to the pyloric glands in the lamina propria. Intestinal type, which characterized by the presence of goblet cells and enterocitlike cells, was detected in only 16% (4 cases) of all the metaplastic patients. No difference was found in the distribution of the two metaplastic types between the two groups (*p* = 0.602). Regarding iNOS and ROS expression, the immunoreactive scores were both significantly higher in *H. pylori-*positive gallbladder mucosa compared to *H. pylori-*negative mucosa (*p* = 0.012 and 0.000, respectively) ([Figure 6](#pone-0070265-g006){ref-type="fig"} and [7](#pone-0070265-g007){ref-type="fig"}). However, in our study, there were only 3% of the slides showed positive *H. pylori* staining and enhanced iNOS or ROS expressions occurring simultaneously in the same area.

![Metaplasia of Chronic Cholecystitis (hematoxylin-eosin stain,×100).](pone.0070265.g005){#pone-0070265-g005}

![iNOS expression in gallbladder mucosa of chronic cholecystitis with *H.* *pylori* infection (A) and without *H. pylori* infection (B) (×100).](pone.0070265.g006){#pone-0070265-g006}

![ROS expression in gallbladder mucosa of chronic cholecystitis with *H.* *pylori* infection (A) and without *H. pylori* infection (B) (×100).](pone.0070265.g007){#pone-0070265-g007}

10.1371/journal.pone.0070265.t003

###### Pathological characteristics of *H.pylori*-positive and negative chronic cholecystitis.

![](pone.0070265.t003){#pone-0070265-t003-3}

  Characteristics                             No. of Patients n(%)               
  ------------------------------------------ ---------------------- ------------ ----------------------------------------
  Postoperative and Pathological Diagnosis                                       
  Gallstone                                                                      
   Cholesterol Stones                              14(25.45)         68(32.08)                      NS
   Pigment Stones                                   8(14.55)         35(16.51)                      NS
   Mixed Stones                                    33(60.00)         109(51.42)                     NS
  Polypoid Lesion                                                                
  Cholesterol Polyp: Inflammatory Polyp               10∶2              45∶2                        NS
  Gallbladder Adenomyomatosis                      35(52.24)         92(35.52)    0.012[▴](#nt107){ref-type="table-fn"}
  Xanthogranulomatous Cholecystitis                 5(7.46)           12(4.63)                      NS
  Histological Analysis of Cholecystitis                                         
  Inflammatory mononuclear infiltrate                                                               NS
   Mild                                            31(46.27)         131(50.58)  
   Moderate                                        22(32.84)         89(34.36)   
   Severe                                          14(20.90)         39(15.06)   
  Degree of Fibrosis                                                                                NS
   Mild                                            45(67.16)         188(72.59)  
   Moderate                                        14(20.90)         54(20.85)   
   Severe                                           8(11.94)          17(6.56)   
  Thickness of Muscular Layer                                                                       NS
   Mild                                            30(44.78)         120(46.33)  
   Moderate                                        22(32.84)         103(39.77)  
   Severe                                          15(22.39)         36(13.90)   
  Adipose Tissue Deposition                                                                         NS
   Mild                                            33(49.25)         166(64.09)  
   Moderate                                        27(40.30)         73(28.19)   
   Severe                                           7(10.45)          20(7.72)   
  Degree of Hyperplasia                                                                             NS
   Diffuse                                         25(37.31)         115(44.40)  
   Focal                                           42(62.69)         144(55.60)  
  Dysplasia                                                                                         NS
   Low-grade                                        3(4.48)           8(3.09)    
   High-grade                                       0(0.00)           0(0.00)    
  Metaplasia                                        9(13.43)          14(5.41)    0.022[▴](#nt107){ref-type="table-fn"}
  Immunoreactive score of iNOS                     6.06±1.59         5.12±1.34    0.012[▴](#nt107){ref-type="table-fn"}
  Immunoreactive score of ROS                      5.01±2.01         3.99±1.87    0.000[\*](#nt106){ref-type="table-fn"}

*p*\<0.01,

*p*\<0.05.

NS: not significant.

N/A: not applicable.

Discussion {#s4}
==========

The presence of *H.pylori* in gallbladder mucosa was first confirmed by Kawaguchi et al in 1996. [@pone.0070265-Kawaguchi1] However, although *H.pylori* has been found 3.5 times more frequently in presence of chronic cholecystitis, whether this agent contributes in the pathogenesis of this biliary disease is still poorly understood. [@pone.0070265-Bulajic1] Firstly, it is difficult to verify the potential entry routes of *H.pylori* to the gallbladder including either ascending duodenum infection or the portal system circulation pathway. [@pone.0070265-Pellicano1], [@pone.0070265-Tiwari1] Secondly, since successful demonstration of *H.pylori* in gallbladder was mostly based on the indirect detection methods such as PCR for *H.pylori-*specific components rather than direct bacterial culture, some investigators believe that *H.pylori* is only a "stagger" but not an "invader" in biliary system. [@pone.0070265-Shukla1], [@pone.0070265-Arnaout1].

Consistent with one previous report from Turkey [@pone.0070265-Abayli1] in our study, *H.pylori* was isolated in 20.55% (67/259) of the patients using culture, staining of gallbladder mucosa and PCR for specific 16s rRNA gene. Among the above three techniques, nest PCR still showed the highest sensitivity. We found that *H.pylori* in the stomach was strongly associated with the infection of this bacterium in gallbladder mucosa. Our data also showed a significant correlation between chronic cholecystitis and a few *H.pylori*-related diseases such as chronic gastritis, gastric ulcer and duodenal ulcer. Considering that *H. pylori-*16s rRNA in gallbladder and gastric-duodenal mucosa from the same individual patient had completely identical sequences, we hypothesize that *H.pylori* in the gastrointestinal system might be a potential candidate for increasing the risk of chronic inflammation of the gallbladder. *H. pylori* might reach the biliary system via sphincter of Oddi by the reflux mechanism. Bacteria colonized in the stomach and small intestine in patients with sphincterotomy and biliary enteric anastomoses, recurrent cholangitis and sphincter of Oddi dysfunction might be the cause of secondary gallstones and cholecystitis. [@pone.0070265-Cetta1], [@pone.0070265-Lary1].

The presenting study revealed that *H.pylori-*infected gallbladder mucosa has a significantly higher prevalence of adenomyomatosis (GAM) than non-infected mucosa (52.24% versus 35.52%, *p* = 0.012). GAM is a benign, degenerative condition characterized by proliferation of the mucosal epithelium and hypertrophy of the muscularis mucosae accompanying with grossly formed mucosal invagination and intramural Rokitansky-Aschoff sinuses. [@pone.0070265-Jutras1] GAM can be diagnosed preoperatively through ultrasound, CT scan or MRI. [@pone.0070265-Stunell1], [@pone.0070265-Poonam1] Incidence rate of GAM is reported to be 25.8%--32% in chronic cholecystitis patients based on the cholecystectomy specimens. [@pone.0070265-Tanno1], [@pone.0070265-Ootani1] Some investigators strongly recommended cholecystectomy in case of GAM with gallstones or symptomatic GAM because stones and chronic inflammation secondary to GAM may lead to dysplasia, metaplasia and cancer. Although no similar finding has been reported with respect to *H.pylori* infection and its association with GAM, we speculate that *H.pylori* might be involved in the development of GAM by altering cell kinetics and proliferative activity which were verified in chronic gastritis and gastric carcinogenesis. [@pone.0070265-Bechi1].

According to literatures, metaplasia of gallbladder mucosa presents in 5%--39% of cholecystectomies. [@pone.0070265-MeirellesCosta1]--[@pone.0070265-Khan1] In our study, metaplasia was identified in 7.67% of the included patients and it was shown to be statistically correlated with *H. pylori* infection in gallbladder mucosa (*p* = 0.047). Metaplasia is believed to be a strong histological sign for diagnosis of moderate or severe chronic cholecystitis because it is rarely observed in gallbladder autospy in which only mild inflammatory changes present. [@pone.0070265-Fernandes1] Misra et al. [@pone.0070265-Misra1] found that *H. pylori* colonises areas of metaplasia in gallbladder producing histological changes very similar to those seen in gastric mucosa. Chen et al. [@pone.0070265-Chen2] demonstrated that metaplasia may provide suitable conditions for *H. pylori* colonization in the gallbladder. Their electron microscopy revealed at sites infected with *H. pylori*, the integrity of the cell-to-cell membrane of gallbladder epithelium was destructed, with swelling of mitochondria and dilatation of endoplasmic reticulum. In *H.pylori-*infected gallbladder nucosa, metaplasia lesions area accompanying with *H.pylori* colonization could be detected in 91.5% of the specimens. These morphological findings may indicate a potential direction for determining the role of *H.pylori* in the formation of metaplasia. Except metaplasia, hyperplasia and dysplasia were detected in 100% and 3.37% of the included patients, respectively. However, no significant correlation could be set up between these two kinds of pathological changes and *H.pylori* colonization in gallbladder mucosa.

*H.pylori* can damage gastrointestinal epithelial cells through mediating chronic inflammation. In the pathogenesis of gastric cancer, *H.pylori* is proved to promote the expression of ROS/RNS mediated by NF-κB, AP-1 and other pathways. [@pone.0070265-Lee2], [@pone.0070265-Cho1] High concentration of NO can lead to nitrative DNA damage and canceration of the epithelium. [@pone.0070265-Naito1] In our study, the expression levels of ROS and iNOS were significantly increased in *H.pylori* infected gallbladder mucosa than that in non-infected mucosa. However, considering there were only 3% of the slides showed positive *H. pylori* staining and enhanced iNOS or ROS expressions occurring simultaneously in the same area, whether *H. pylori* could directly induce oxidative stress in gallbladder mucosa through increasing the expression of iNOS or ROS in gallbladder mucosa still needs further investigation. Recently, a study *in vitro* showed that *H.pylori* could significantly stimulate the growth of cholangiocarcinoma cell line (KKU-100) and DNA synthesis through iNOS pathway. [@pone.0070265-Boonyanugomol1] Unfortunately, no study so far has explored the role of *H.pylori* in the development of chronic cholecystitis in normal gallbladder epithelium with respect to cell proliferation, apoptosis, and inflammation.

Conclusions {#s4a}
-----------

In summary, our study indicated that *Helicobacter pylori* infection in gallbladder mucosa is strongly associated with *Helicobacter pylori* existed in the stomach. *Helicobacter pylori* is also correlated with gallbladder premalignant lesions including metaplasia and adenomyomatosis. The potential mechanism might be related with higher ROS/RNS production in *Helicobacter pylori-*positive gallbladder mucosa.
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